β-Amyloid (1-40)

CAT:
804-HY-P0265-01
Size:
10 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
β-Amyloid (1-40) - image 1

β-Amyloid (1-40)

  • UNSPSC Description:

    β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease.
  • Target Antigen:

    Amyloid-β
  • Type:

    Peptides
  • Related Pathways:

    Neuronal Signaling
  • Applications:

    Neuroscience-Neurodegeneration
  • Field of Research:

    Neurological Disease
  • Assay Protocol:

    https://www.medchemexpress.com/_beta_-Amyloid_1-40.html
  • Purity:

    98.14
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
  • Smiles:

    O=C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC2=CNC=N2)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(NCC(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC4=CNC=N4)C(N[C@@H](CC5=CNC=N5)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CC6=CC=CC=C6)C(N[C@@H](CC7=CC=CC=C7)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](C(C)C)C(NCC(NCC(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(O)=O)N
  • Molecular Weight:

    4329.82
  • References & Citations:

    [1]Shoji M, et al. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Front Biosci. 2002 Apr 1;7:d997-1006.|[2]Cleary J, et al. Beta-amyloid(1-40) effects on behavior and memory. Brain Res. 1995 Jun 5;682(1-2):69-74.|[3]Olariu A, et al. Memory impairment induced by chronic intracerebroventricular infusion of beta-amyloid (1-40) involves downregulation of protein kinase C. Brain Res. 2002 Dec 13;957(2):278-86.Appl Surf Sci. 2023 Sep 9, 158427.|Brain Res. 2024 Apr 10:1835:148932.|Chem Eng J. 2024 Dec 15.|Evid Based Complement Alternat Med. 2022 Sep 9;2022:3100621.|Nano Res. 28 April 2022.|Nanomaterials. 2022 Nov 16;12(22):4031.|Adv Sci (Weinh). 2023 Nov 10:e2303402.|Korean J Physiol Pharmacol. 2024 Jul 1;28(4):361-377.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    131438-79-4